The increase of import and export promotes the transformation of foreign trade mode of Medicine

Trade balance continues to improve the growth rate of European and American markets, slows down the speed of industrial transformation, and speeds up the pace of industrial transformation in recent years Under the joint effect of changes in the global pharmaceutical market pattern and strong domestic demand development of China's medicine, China's pharmaceutical import and export trade has achieved a significant growth From January to October this year, the total import and export volume of medicine reached 59.349 billion US dollars, an increase of 39.66% year on year Among them, export reached 36.297 billion US dollars, an increase of 35.87%; import reached 23.052 billion US dollars, an increase of 46.08% Generally speaking, the stable development trend of the global pharmaceutical market provides a favorable market environment for the development of China's pharmaceutical foreign trade, but there are still many uncertain factors, the global economic recovery is slowing down, the downside risks are increasing, the growth rate of pharmaceutical trade is falling, the traditional advantages of China's pharmaceutical industry are facing new challenges, the export development mode is facing changes, and the high-end market needs to be broken through, with challenges and opportunities in common Deposit From the data from 2008 to now, the growth rate of China's pharmaceutical export has fully recovered to the level before the financial crisis (see Figure); thanks to the increase of domestic market capacity, China's pharmaceutical import trade is also accelerating From January to October of this year, China's pharmaceutical export increased by 9.6 billion US dollars, mainly from three parts First, the global pharmaceutical industry layout accelerated transfer, some characteristic API procurement turned to China, and the export of high-end pharmaceutical products increased significantly According to incomplete statistics, the resulting increase in exports is about US $2.5 billion, accounting for 26% of the total increase; secondly, the market share of traditional Chinese medicine products continues to increase, including US $2.8 billion in developed markets such as Europe, America and Japan, and US $3.5 billion in emerging markets, accounting for 63% of the total increase; thirdly, some domestic medical equipment exports are developing towards the middle and high-end, effectively entering developed countries such as Europe and America Market, the increase is about 800 million US dollars, accounting for 8% of the increase In addition, domestic demand maintained a strong growth momentum, and the growth rate of pharmaceutical import reached a record high The surplus accounted for 22.32% of the import and export volume, down 3.4 percentage points from the same period last year, and the trade balance continued to improve European and American market growth slows down According to GTI data, in the first nine months of 2011, the volume of global pharmaceutical trade generally increased The volume of EU and US pharmaceutical trade was US $135.8 billion and US $76.7 billion, respectively, with a year-on-year growth of 8.02% and 1.76%, respectively, with growth rates falling by 3.57 and 7.81 percentage points; the overall unit price of pharmaceutical trade showed a downward trend, in which the average price of us pharmaceutical imports fell by 4.67% and EU by 7.77% According to the data, the pharmaceutical imports from developing countries in Europe and the United States increased significantly, among which the imports from China by the United States, the European Union, Japan and Australia increased by 29.06%, 31.39%, 26.37% and 136.18% respectively (see table) The emerging pharmaceutical market continues to maintain relatively rapid development, and the market growth of Russia, Australia, ASEAN and Ukraine is significantly higher than that of developed markets According to GTI data, from January to September, the growth rate of pharmaceutical import in the above markets reached 13.45%, 20.2%, 19.61% and 21.32% respectively, and the growth rate of African market was about 10% Since the second half of the year, some Chinese enterprises have increased their efforts to explore emerging markets, and the share of Chinese pharmaceutical products in emerging markets continues to increase Among them, the growth rate of APIs, medical devices, especially diagnosis and treatment equipment products is the most significant According to the customs data, the growth rate of API and medical equipment products in China reached 38.14% and 69.97% respectively from January to October Bulk API accounted for 30% - 40% of the market share in emerging markets The market share of medical equipment products in Russia, Brazil, ASEAN and other markets increased significantly for three consecutive years, reaching 11.75%, 8.32% and 8.69% respectively The growth potential of emerging markets will remain in the next two years Look good In recent years, with the acceleration of industrial transformation, the international pharmaceutical industry has been transferred to Asia, which has directly driven the export of Chinese characteristic APIs and Western pharmaceutical preparations to grow significantly From January to October this year, the export of Western pharmaceutical preparations reached US $1.715 billion, a year-on-year increase of 37.95%, higher than the average growth rate of the export of medical insurance products, especially for the EU and Australia markets, with a growth rate of 69.44% and 1166.58% respectively At the same time, the transformation speed of domestic pharmaceutical enterprises from APIs to specialty APIs and preparations is accelerating, and the export scale of some enterprises, especially Zhejiang and Jiangsu pharmaceutical enterprises, continues to expand From January to October, China's medical device export reached 12.657 billion US dollars, a year-on-year increase of 54.17%, accounting for an increase of 4 percentage points to 34.87% From the perspective of product structure, conventional medical device products continue to maintain the competitive advantage of high quality and low price The export of medical dressings, disposable consumables, health rehabilitation products, oral equipment and materials increased by 106.75%, 49.16%, 41.34% and 58.37% respectively Developed markets such as Europe, the United States and Japan have a stable position, with growth rates of 56.98%, 47.02% and 41.75% respectively, and their market share continues to increase At the same time, the export of high-end medical equipment represented by X-ray machine, CT, MRI, ultrasound and nuclear imaging equipment increased significantly, among which, the export of MRI equipment increased by 23.97% year-on-year, and the export of X-ray tomograph and color ultrasonic diagnostic equipment increased by more than 20% It is worth noting that the export of high-end medical equipment is still dominated by "three capital" enterprises, accounting for the proportion of export 81.32% The export of APIs continued to climb The export of APIs got rid of the impact of the financial crisis The export volume further increased, with an increase of 29.28% The export volume reached 18.198 billion US dollars, with an increase of 28.19% However, the average price remained at the bottom, down 0.84% year on year Among them, the export volume to India increased by 32.42%; at the same time, China's API continued to occupy the basically saturated EU and North America markets, and the market share of traditional bulk API and characteristic API with competitive advantage continued to increase; in addition, the pharmaceutical industry in ASEAN, Brazil and Eastern Europe started to develop, and the demand for API continued to expand, which is favorable for China's API export volume Rise From January to October, the export of traditional Chinese medicine increased by 42.27%, the export of extract and traditional Chinese medicine increased by 49.2% and 28.25% respectively year on year, and the weight of Asian market continued to expand, accounting for 57.66% of the export of traditional Chinese medicine However, influenced by the EU traditional herbal medicine directive, China's export of Chinese patent medicine to the EU this year showed an obvious trend of high in the first place and low in the second The export peak appeared in March, with a growth rate of 506.37%, and then dropped to 70% in the same period last year in the next few months Due to the slow recovery of the global economy, the limited growth of the European and American pharmaceutical market, there is some uncertainty in the continued substantial growth of the emerging pharmaceutical market, the sustained growth of the demand of the international pharmaceutical market is not optimistic, and the risk of China's pharmaceutical export increases But at the same time, the European, American and Japanese markets still have potential to be explored, and the export of high-end and medium-sized pharmaceutical products in China has achieved initial results; the market diversification strategy space is huge, and the advantages of Chinese pharmaceutical products will be further reflected, which is conducive to further expanding market share of enterprises Considering all kinds of factors, China's foreign trade in medicine will continue to grow in 2012, but the growth rate will slow down.